36 recruiting, 23 not yet recruiting, 18 active not recruiting, 5 completed. 65 Phase 2, 25 Phase 1, 4 Phase 3, 1 Early Phase 1.
Follow this drug Literature Review of glofitamab trials Research Report on glofitamab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse Large B Cell Lymphoma Glofitamab, Radiotherapy, Obinutuzumab - Relapsed /Refractory DLBCL | Phase 2 | Not yet recruiting | Olivia Newton-John Cancer Research Institute | 40 | 2026-12-01 | 2026-06-08 |
| TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma Tafasitamab, Polatuzumab vedotin, Glofitamab - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma | Phase 2 | Not yet recruiting | Brown University | 30 | 2026-11-01 | 2026-09-01 |
| Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma Biospecimen Collection, Cisplatin, Computed Tomography - Ann Arbor Stage II Mantle Cell Lymphoma, Ann Arbor Stage III Mantle Cell Lymphoma | Phase 1 | Not yet recruiting | National Cancer Institute (NCI) | 16 | 2026-10-30 | 2026-09-03 |
| Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma Biospecimen Collection, Bone Marrow Biopsy, Carboplatin - Recurrent Burkitt Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements | Phase 2 / Phase 3 | Not yet recruiting | National Cancer Institute (NCI) | 271 | 2026-10-30 | 2026-08-19 |
| GLORY: Glofit-GemOx With Liso-Cel For Lymphoma Obinutuzumab, Glofitamab, Gemcitabine & oxaliplatin - Lymphoma, B-cell Lymphomas | Phase 2 | Not yet recruiting | Massachusetts General Hospital | 56 | 2026-10-14 | 2026-07-17 |
| AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study") Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - AIDS-Related Diffuse Large B-cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 1 | Not yet recruiting | National Cancer Institute (NCI) | 15 | 2026-10-09 | 2026-08-13 |
| A Study of Polatuzumab Vedotin and Glofitamab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Within 12 Months After R-CHOP Polatuzumab vedotin, Glofitamab - Diffuse Large B-cell Lymphoma | Phase 2 | Not yet recruiting | Yonsei University | 47 | 2026-09-01 | 2026-07-14 |
| Glofitamab in B-NHL Using Mid-Therapy Intratumoral Transcriptomics Glofitamab - Relapsed/Refractory Diffuse Large B-cell Lymphoma, Relapsed/Refractory Mantle Cell Lymphoma | Phase 2 | Not yet recruiting | Joshua Brody | 16 | 2026-09-01 | 2026-08-05 |
| Bispecific Antibody-Based Holding/Bridging Therapy Before CAR-T in Aggressive B-Cell Lymphomas Glofitamab, Epcoritamab, Polatuzumab Vedotin - Aggressive B-cell Non-Hodgkin Lymphoma (aNHL), Relapsed or Refractory B-cell Lymphoma | Phase 2 | Recruiting | National Research Center for Hematology, Russia | 40 | 2026-09-01 | 2026-10-20 |
| Sonrotoclax, Glofitamab, Gemcitabine, and Oxaliplatin for Relapsed or Refractory Large B-Cell Lymphoma Sonrotoclax, Glofitamab, Gemcitabine (1000 mg/m2) - Large B-Cell Lymphoma (LBCL), High-grade B-cell Lymphoma | Phase 2 | Not yet recruiting | The First Affiliated Hospital of Soochow University | 39 | 2026-08-20 | 2026-08-19 |
| Hypofractionated Radiotherapy Plus GM-CSF, Pomalidomide and Glofitamab for Newly Diagnosed PCNS-DLBCL hypofractionated radiotherapy plus GM-CSF, pomalidomide and glofitamab - DLBCL - Diffuse Large B Cell Lymphoma, PCNSL (Primary CNS Lymphoma) | Phase 2 | Recruiting | The First Affiliated Hospital of Xiamen University | 53 | 2026-07-25 | 2026-08-06 |
| A Study of Glofitamab Plus GemOx Compared With Standard of Care in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Obinutuzumab, Glofitamab, Gemcitabine - Diffuse Large B Cell Lymphoma (DLBCL) | Phase 2 | Not yet recruiting | The First Affiliated Hospital of Soochow University | 96 | 2026-07-22 | 2026-07-13 |
| Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy Biospecimen Collection, Computed Tomography, Glofitamab - Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 20 | 2026-07-08 | 2026-09-09 |
| Real-World Study of Bispecific Antibody in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma Glofitamab - Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma | Not yet recruiting | Yanyan Liu | 200 | 2026-07-01 | 2026-07-10 | |
| AI-Driven Treatment Strategy vs ZR2 in Older Treatment-naive Patients With LBCL Polatuzumab Vedotin, Rituximab (R), Zanubrutinib - Large B-Cell Lymphoma (LBCL) | Phase 2 | Not yet recruiting | Ruijin Hospital | 112 | 2026-06-30 | 2026-07-21 |
| Study With Glofitamab in Patients With MCL and Inadequate Response or Relapse Following CAR T-cell Therapy Glofitamab - Mantle Cell Lymphoma | Phase 2 | Recruiting | Fondazione Italiana Linfomi - ETS | 41 | 2026-06-05 | 2026-06-25 |
| External Beam Radiotherapy Followed by Bispecific Antibody Therapy for Relapsed/Refractory DLBCL Epcoritamab, Glofitamab, External Beam Radiation Therapy - Diffuse Large B Cell Lymphoma | Phase 1 | Recruiting | University of Utah | 12 | 2026-06-01 | 2026-06-04 |
| AI-Driven Treatment Strategy vs Pola-R-CHP in Untreated LBCL Polatuzumab Vedotin, rituximab, Cyclophosphamide - Large B-Cell Lymphoma (LBCL) | Phase 2 | Not yet recruiting | Ruijin Hospital | 178 | 2026-05-06 | 2026-05-19 |
| Rimegepant Plus Glofitamab and CD19 CAR-T Therapy in R/R LBCL Rimegepant, Glofitamab, Obinutuzumab - Relapsed/Refractory Large B-cell Lymphoma (LBCL) | Phase 2 | Not yet recruiting | Ruijin Hospital | 100 | 2026-05-01 | 2026-05-29 |
| Glofitamab as a Bridge to and/or Consolidation Post Autologous Stem Cell Transplant in Patients With Relapsed B Cell Lymphomas Glofitamab - Diffuse Large B Cell Lymphoma Refractory | Phase 2 | Not yet recruiting | American University of Beirut Medical Center | 40 | 2026-04-15 | 2026-02-04 |
Showing 20 of 89. Sign in to see all of them.
Lymphoma, Large B-Cell, Diffuse (27) · Recurrence (17) · Lymphoma, B-Cell (13) · Lymphoma, Mantle-Cell (13) · Lymphoma (10) · Lymphoma, Non-Hodgkin (10) · Dendritic Cell Sarcoma, Interdigitating (6) · Aggression (1) · Burkitt Lymphoma (1) · Cytokine Release Syndrome (1) · Immunoblastic Lymphadenopathy (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Follicular (1) · Lymphoma, Primary Effusion (1)
Hoffmann-La Roche (17) · Ruijin Hospital (8) · National Cancer Institute (NCI) (4) · City of Hope Medical Center (3) · M.D. Anderson Cancer Center (3) · The First Affiliated Hospital of Soochow University (3) · The Lymphoma Academic Research Organisation (3) · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest (2) · Memorial Sloan Kettering Cancer Center (2) · Navy General Hospital, Beijing (2) · The First Affiliated Hospital of Xiamen University (2) · ADC Therapeutics S.A. (1) · Abramson Cancer Center at Penn Medicine (1) · American University of Beirut Medical Center (1) · Arvinas Inc. (1)
United States (39) · China (30) · France (16) · Australia (15) · Italy (14) · Spain (14) · United Kingdom (12) · Denmark (10) · Canada (9) · Germany (9) · South Korea (9) · Belgium (7) · Poland (7) · Brazil (4) · Taiwan (4)
Salah-Eddin Al-Batran, Prof. Dr. (2) · Adam Olszewski (1) · Ali Bazarbachi, MD (1) · Anita Kumar, MD (1) · Cao Xinxin (1) · Christine Ryan, MD (1) · Cole H Sterling (1) · Dai Chihara, MD,PHD (1) · Dehui Zou (1) · Diego Villa (1)
PMID 40749164, PMID 33739857, PMID 34941996, PMID 34953862, PMID 36507690, PMID 36521030, PMID 38437725, PMID 39319495, PMID 39365960, PMID 39550172, PMID 40532125, PMID 40550489, PMID 40802906, PMID 41115257, PMID 41670385, PMID 41894687, PMID 41979332, PMID 42255257, PMID 42269085, PMID 42393723, PMID 42463852, PMID 42837325
2023 (4), P30CA033572 (3), 2016 (1), 2017 (1), 2019 (1), 2025 (1), U10CA180821 (1), UM1CA121947 (1), UM1CA186691 (1), UM1CA186717 (1)